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CISNE: An accurate description 
of dose-effect and synergism in 
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José I. Martín1,5 & Jaime Ferrer1,5
The precise determination of dose-effect curves and the combination effect of drugs is of crucial 
importance in the development of new therapies for the most dreadful diseases. We have found that 
the current implementations of the theory of Chou et al. are not accurate enough in some circumstances 
and might lead to erroneous predictions of synergistic or antagonistic behaviour. We have identified the 
source of inaccuracies and fixed it thereby improving the accuracy of those methods. Here we explain 
the main features of our approach and demonstrate its higher accuracy as compared to the standard 
methods. Therefore, this new implementation might have a huge impact in the reliability of future 
research on new Combination Therapies.
Combination Therapies have been a valuable approach for the treatment of diseases since the origins of medicine. 
Traditional Chinese medicine has been using mixtures of natural herbs for more than 2000 years1. Nowadays, 
the use of adequate drug combinations allows to increase beneficial effects using lower doses of each constituent 
and therefore to reduce their adverse effects, as well as to minimize the induction of drug resistance2. It can also 
provide selective synergism against a particular target. For these reasons, Combination Therapies are widely used 
for the treatment of the most dreadful diseases, such as cancer3,4 or AIDS5,6.
Potential drug combinations are frequently tested first in cell cultures in preclinical environments, whereby 
the successful combinations are subsequently transferred to animal experimentation, clinical testing and clinical 
practice. However, the transition from a biologically controlled environment to the clinical practice often results 
in failures7,8. This lack of success is possibly caused by the difficulty to reproduce the overall physiological con-
ditions in the laboratory. However, they would also occur if both drugs act on the same cellular sub-clone. We 
finally note that some of those failures might be originated by an insufficiently accurate statistical analysis of the 
cell cultures that may provide false positives or negatives in specific situations. The goal of the present article is 
to eliminate this last source of errors by implementing drastic improvements of the referred statistical analysis
Computational methods can be applied to assist on the determination of the effect of Combination Therapies. 
First, they can be used in an effort to predict, previous to experimental verification, potential drug combina-
tions9–11. Also, they can be used after experiments to analyse statistically the measured data in order to quan-
tify the presence or absence of synergism12,13, that is the subject matter of the present work. Currently available 
methods12,13 to quantify the synergistic effect of drug combinations from experimental data predict accurate 
dose-effect relationships in many cases (Fig. 1(a1)), which lead to a correct prediction of the synergism results 
(Fig. 1(a2)). However, we have found that they fail to reproduce the experimental data in quite a few others 
(Fig. 1(b1)). This lack of precision may result in an inaccurate or even erroneous description of the synergis-
tic properties of drug combinations (Fig. 1(b2)). Therefore, there is an urgent need to develop a method that 
improves the accuracy of the dose-effect description, which then enables us to identify synergism effects in exper-
iments with a minimal uncertainty.
Although drug synergism might seem an intuitive concept, its formal definition is not so simple and it has 
been a focus of controversy during the past century14–16. A combination of drugs is synergistic when the combined 
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effect is larger than the additive effect of each individual drug. Similarly, the combination is antagonistic when its 
combined effect is smaller than the additive effect of each individual drug. Trouble arises however from the defini-
tion of the additive effect. Let us assume that two drugs A and B have an effect that we quantify with the numbers 
EA and EB (e.g.: the number of affected cells in a system). We define tentatively the additive effect of the two drugs 
as EA + EB. However, this definition would be true only if the dose-effect relationships of each drugs were linear, 
which is usually not the case. The modern definition of drug synergism16–21 is based on the work by Chou et al., 
who define the median-effect equation (MEE)22–24 as the universal equation for the non-linear dose-effect rela-
tionship. This definition is based on physicochemical processes, and its validity does not depend upon factors that 
are specific of each system such as the mechanism of the enzymatic reaction or the kinetic nature of the inhibitor. 
From that, they define the Combination Index (CI)25,26 to quantify the synergistic effect of a drug combination. 
A given drug combination is said to be additive when its CI equals 1. The degree of synergism (or antagonism) is 
measured by the deviation of CI from 1, the smaller (the larger) the CI, the stronger the synergistic (antagonistic) 
effect of the combination is. Therefore, in order to analyse synergism in a drug combination, a full and accurate 
description of the dose-effect relationship of each drug separately, as well as of their combination at a fixed drug 
ratio, is needed16.
In this work, motivated by our need to obtain results as accurate as possible from synergism studies, we have 
analysed the numerical problems of the currently available methods such as calcusyn12 and compusyn13. We 
present our new implementation of the theory of Chou et al., which solves these problems, thus increasing the 
precision and reliability of previous methods. We have made the new implementation freely available through 
the use of our new program CISNE (Code for the Identification of Synergism Numerically Efficient)27. Therefore, 
our new method keeps the generality of a theory that has been widely validated and applied to a variety of biolog-
ical systems28, but, at the same time, it represents an improvement on the implementation of that theory. This is 
because it allows to determine accurately possible synergistic effects in biological systems within a wide range of 
characteristic parameters where the previous methods failed.
The theory of synergism
In a dose-effect experiment several doses x of a drug are applied to a population (e.g.: a cell culture), and their 
effect is determined by measuring the fraction of the population affected by the drug after a certain period of 
time, fa. Current practice actually plots the fraction unaffected fu = 1 − fa, as a function of x, as we show in Fig. 1. 
Based on physicochemical analyses, Chou et al. encapsulated the dependence of fa on the dose in terms of the 
following non-linear universal equation (MEE)22,23:
=f f x D/ ( / ) (1)a u
m
where D and m are parameters that depend on each given drug. D is the dose at which fa = 0.5, whereas m deter-
mines the shape of the dose-effect curve. Here m = 1, >1 or <1 indicate hyperbolic, sigmoidal or flat sigmoidal 
curves, respectively. Examples of these different curves are given in Fig. 2(a).
Synergism is characterized by the combination index CI, that is always given as a function of fa. We discuss in 
some detail here the combination index for two drugs, although the formalism can be extended for N drugs. The 
combination index for drugs A and B combined in a ratio R A:R B is given by
Figure 1. Example of a dose(in arbitrary units a.u.)-effect(unaffected fraction fu) data (green diamonds) for 
which currently available methods (red lines) reproduces accurately the shape of the dose effect curve (panel 
(a1)) or completely fails to reproduce it (panel (b1)). This can lead to a correct determination of the synergism 
(panel (a2)) or to a completely wrong result (panel (b2)). The exact result (black dashed lines), obtained from 
exact data previous to introduce a experimental deviation, is also shown. Insets of panels (a1) and (b1) show the 
linear regression used to fit the data.
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where mA,B,A+B, DA,B,A+B are the MEE parameters obtained for drugs A or B alone or in the combination A + B. 
Notice that a not sufficiently accurate determination of any of these parameters may lead to erroneous estimates 
of CI.
We discuss now how popular implementations of Chou’s theory12,13 determine the important parameters m 
and D of a given drug and give some hints on the source of their inaccuracies. First, Eq. (1) is converted to the 
linear relationship.
′ = ′ +y mx b (4)
where y′ = log(fa/fu), x′ = log(x) and b = −mlog(D). Then the experimental data points are fitted to Eq. (4) using 
a linear least squares fit. This procedure delivers estimates for m and b. The remaining parameter is obtained 
from D = e−b/m. This approach is accurate whenever the experimental data points obey closely the theoretical 
dose-effect curves. In practice, the experimental dose-effect data obtained from biological samples always contain 
some non negligible dispersion whose impact need not be negligible.
Why current implementations fail
We illustrate the impact of actual experimental data dispersion via an example. Imagine an experiment in a cul-
ture where the measured fraction unaffected of the population fu leads to the any of the curves plotted in Fig. 2(a). 
Here we give the same standard deviation σ to each experimental data point. We plot now the same data points 
in a logarithmic scale in Fig. 2(b), so that the axes represent x′ and y′. The figure demonstrates that a constant 
σ for fu leads to a non constant standard deviation σ′ for y′. Importantly, σ′ increases hugely at the sides of the 
curve specially if m is sufficiently large. This pathology is made more evident in Fig. 2(c), where we show how y′ 
and σ′ depend on fa. The figure shows that σ′ increases and eventually diverges as we move away from fa = 0.5. 
This means that the linear least squares fit procedure gives artificially more weight to those experimental points 
having fa closer to 0 or 1. Therefore, the results are artificially biased. We will show below that this artifact can 
harm substantially the quality of the results even leading to false positives or false negatives verdicts of synergistic 
behaviour.
Our new implementation in CISNE avoids the above pathology from the outset. We take advantage of modern 
curve fitting algorithms, that obtain m and D directly from a nonlinear least squares fitting29 of equation (1). This 
approach presents two main advantages:
 1. All the data points share the same weight, that is independent of the value of fa thus avoiding any bias.
 2. Experimental data points having fa ≥ 1 or fa ≤ 0 happen experimentally due to experimental fluctuations 
and carry information that should not be ignored. The linear least squares fitting does ignore them and 
misses relevant information while the nonlinear least squares fitting does not present this limitation, and 
therefore no data information is lost.
Figure 2. (a) Dose-effect relationships in terms of a median effect equation with D = 10 and different values 
of m. Dose values x and D are given in arbitrary units. Theoretical data points with a fixed standard deviation 
σ(fa) = 0.05 are also included. (b) Linear fitting variables x′ and y′ plotted using the same data of panel (a). (c) 
Dependence of y′ and of its standard deviation σ(y′) with the value of fa for a fixed value of σ(fa) = 0.05.
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A false positive and a false negative
We show now two examples where the current implementation fails while CISNE reproduces the correct behav-
iour. In the first example, two drugs A1 and B1 show purely additive behaviour (CI = 1), however the current 
implementation predicts strong synergism ( CI 1). We generate dose-effect data points numerically for the two 
drugs and for their combination A1 + B1 in a 1:1 ratio, that we show in the upper left panel in Fig. 3. Notice that 
we have introduced random deviations in the data points following a standard deviation σ = 0.05 to try and 
mimic experimental data. The generated dose-effect data is given in Table 1 of the Additional Information. The 
upper left panel of Fig. 3 shows the results of the dose-effect fitting curve with the standard (red lines) and the 
CISNE (blue lines) methods, as well as the exact curve before introducing the experimental deviations (black 
dashed lines). The panel shows that the current implementation reproduces well some of the dose-effect relation-
ships but it fails for others, while CISNE fits accurately the experimental data points. More important however are 
the predictions for the combination index obtained from the fitted curves, that are shown in the upper right panel 
of the figure, together with their 95% confidence interval. Here CISNE reproduces quite correctly the additive 
behaviour of the combination while the standard method predicts a strong synergistic effect leading to a false 
positive.
In the second example, two drugs A2 and B2 show a strongly synergistic behaviour (CI = 0.6). We generate 
dose-effect data points for the two drugs and for their combination A2 + B2 in a 1:1 ratio, where we include ran-
dom deviations as before. The dose-effect curves are plotted in the lower left panel of Fig. 3 and the corresponding 
data are given in Table 2 of the Additional Information. The panel also shows the curves fitted with the standard 
method as well as with CISNE. As in the former example, we find that CISNE fits the experimental data points 
much more accurately. We use these curves to determine the combination index. We plot our results in the lower 
right panel of Fig. 3 together with their 95% confidence interval. We find that CISNE reproduces accurately 
the synergistic behaviour while the standard method predicts additivity or even antagonism leading to a false 
negative.
Notice that the wrong results with the standard method are a consequence of the inaccurate description of 
some of the dose-effect data by the fitted curves, especially in the central range of fu, which is not visible in the 
Figure 3. Dose-effect fitting and combination index CI obtained for a theoretical additive combination A1 + B1 
(upper panels) and a theoretical synergistic combination A2 + B2, as described in the text, with the standard 
method (red lines) and with the new CISNE method (blue lines), compared to the exact result (black dashed 
lines). Each dose-effect panel includes an inset with the result of the linear regression used by the standard 
method. Blue and red shaded regions in the CI indicate the 95% confidence interval of the results obtained with 
the standard method and with CISNE, respectively.
drug A1 drug B1 drug combination A1 + B1
x fa x fa x fa
0.625 0.999 0.625 0.997 0.625 0.956
1.25 0.992 1.25 0.970 1.25 0.933
2.5 0.963 2.5 0.959 2.5 0.919
5 0.789 5 0.782 5 0.745
10 0.469 10 0.484 10 0.559
20 0.182 20 0.221 20 0.134
40 0.115 40 0.045 40 0.047
80 0.046 80 0.009 80 0.003
160 0.012 160 0.005 160 0.003
Table 1. Generated dose x and fraction affected fa data of a combination of drugs A1 + B1 with additive behavior.
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linear fittings shown in the insets of Fig. 3 (where r > 0.96 in all cases indicating an accurate linear fitting). In the 
first example the fitted curve underestimates the effect of drug A1 (the fitted curve is shifted to the right respect 
to the dose-effect data points), but it overestimates the effect of the drug combination A1 + B1 (the fitted curve is 
shifted to the left respect to the dose-effect data points). This combined effect leads to a large overestimation of 
the effect of the combination of drugs A1 + B1 respect to their individual effect, and in this case to a false positive. 
Similarly, in the second example the effect of drug B2 is overestimated and the effect of the drug combination 
A2 + B2 is underestimated, leading to a large underestimation of the effect of the combination of drugs A2 + B2 
respect to their individual effect, and, therefore, to a false negative in this case.
drug A2 drug B2 drug combination A2 + B2
x fa x fa x fa
0.625 0.992 0.625 0.988 0.625 0.999
1.25 0.964 1.25 0.951 1.25 0.998
2.5 0.923 2.5 0.924 2.5 0.911
5 0.838 5 0.828 5 0.673
10 0.648 10 0.624 10 0.365
20 0.202 20 0.263 20 0.104
40 0.107 40 0.054 40 0.037
80 0.067 80 0.020 80 0.020
160 0.058 160 0.005 160 0.018
Table 2. Generated dose x and fraction affected fa data of a combination of drugs A2 + B2 with synergistic behavior.
Figure 4. Results of 100000 Monte Carlo simulations for the parameter D and its standard deviation σ(D), 
obtained with the standard procedure and with the new method implemented in CISNE, for curves of different 
expected sigmoidality E[m].
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More computational experiments
In order to evaluate the precision of the new methodology implemented in CISNE compared to the standard 
procedure more rigorously, we have analysed the MEE parameters and CI obtained from experimental data gen-
erated computationally by means of Monte Carlo simulations30,31. In these simulations we consider the data points 
shown in Fig. 2(a), which for the parameters D and m lead to expected values of the parameters E[D] = 10 (in 
arbitrary units) and E[m] = 0.5, 1, 2. The generated data includes 9 different drug concentrations, including x = D 
and 4 concentrations above and below D, with 2 adjacent concentrations differing in a factor of 2. For each data 
point, a randomly generated error is included in fa following a normal distribution with a standard deviation 
σ(fa) = 0.05. From these generated data for each curve the values of D and m are recalculated with both the stand-
ard and the new CISNE methods, and compared to their expected values E[D] and E[m]. Standard deviations 
σ(D) and σ(m) are also calculated from the fitting procedures. Each computational experiment is repeated 100000 
times to obtain statistical significant results.
The results of the fitting of the simulated data sets to the MEE are summarized in the histograms of Figs 4 and 5. 
In Fig. 4 we show the obtained values of D and its standard deviation σ(D). Notice that σ(D) is a measurement of 
the confidence interval of D from each of the experimental data sets separately, and it is not related to the standard 
deviation of the gaussian-like representations of D in the left panels of Fig. 4, which contain the information from 
all the experiments together. As expected, the obtained results for D follow a normal distribution centered at its 
expected value E[D] = 10. For the flat sigmoidal curve (m = 0.5), the results of the standard procedure and of the 
new CISNE method are very similar. This makes sense, as the selected data shown in Fig. 2(a) presents values 
of fa which do not come very close to 0 or 1, and therefore almost all our data points stay in the central region of 
Fig. 2(c), where the change in the standard deviation of the points is not very important. However, the benefit of 
the new approach becomes apparent for hyperbolic (m = 1) and sigmoidal (m = 2) curves. This is accompanied 
by smaller values of σ(D). Therefore, CISNE allows to obtain values of D much closer to the real value, and with 
better confidence intervals, especially for m ≥ 1.
Figure 5 shows the obtained results for m and its standard deviation σ(m). The difference between the standard 
and the CISNE approach becomes even more clear in this case. CISNE presents gaussian distributions centered at 
the corresponding expected values E[m] = 0.5, 1 and 2, as expected. On the other hand, the standard procedure 
leads to a distribution with a maximum at m slightly lower than 1 for the hyperbolic curve and much lower than 2 
Figure 5. Results of 100000 Monte Carlo simulations for the parameter m and its standard deviation σ(m), 
obtained with the standard procedure and with the new method implemented in CISNE, for curves of different 
expected sigmoidality E[m].
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for the sigmoidal curve. Moreover, the standard deviations σ(m) obtained with the standard procedure are lower 
than the ones obtained with the CISNE method (notice that in both cases σ(m) increases with E[m] = 0.5, but its 
relative value σ(m)/E[m] = 0.5 remains almost constant). Therefore, meanwhile CISNE reproduces accurately the 
results of m, the standard procedure can not only lead to wrong results, but could also lead to wrong confidence 
intervals which do not correspond to reality, leading to a false impression of accuracy in the results.
In order to analyse the accuracy of both methods in the determination of the CI, we perform blocks of 3 simu-
lations with the same methodology as before, and we assign the first one to drug A, the second to drug B and the 
third to the drug combination A + B in a 1:1 ratio. As the 3 simulations have the same expected values of m and D, 
the obtained effect should be just additive and CI(fa) = 1. However, deviations from this value are expected from 
the effect of the experimental fluctuations. We repeat these blocks of simulations 100000 times for E[m] = 0.5, 1, 
2 and the results of CI(fa = 0.5) and its standard deviation σ(CI(fa = 0.5)) are summarized in Fig. 6.
Figure 6. Results of 100000 Monte Carlo simulations for the combination index at fa = 0.5 and its standard 
deviation σ(D), obtained with the standard procedure and with the new method implemented in CISNE, for 
curves of different expected sigmoidality E[m].
E[m] method
CI(fa = 0.5) < 0.8 
(synergistic)
0.8 < CI(fa = 0.5) < 1.2 
(additive)
1.2 < CI(fa = 0.5) 
(antagonistic)
0.5
standard 13.47% 66.54% 19.99%
CISNE 11.99% 69.86% 18.15%
1
standard 12.87% 67.69% 19.44%
CISNE 3.73% 88.56% 7.72%
2
standard 15.11% 63.06% 21.84%
CISNE 0.58% 97.37% 2.05%
Table 3. Percentage of our computational experiments of drug combinations that can be considered synergistic, 
additive or antagonistic based on the results of the standard and CISNE methods, and for different values of E[m].
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The results obtained with the standard and the new CISNE methods are similar for E[m] = 0.5, but the advan-
tage of the new method is clear for E[m] = 1 and E[m] = 2. We show in Table 3 the percentage of the simulations 
that are inside an interval where we can consider synergistic (fa < 0.8), additive (0.8 < fa < 1.2), and antagonistic 
(1.2 < fa) effect. CISNE allows to strongly reduce the number of false positives of synergistic and antagonistic 
effect, especially for E[m] = 2, where the standard method leads to more than one third of simulations indicating 
non-additive effect, meanwhile this value is reduced to less than 3% of the experiments with the CISNE method. 
Notice that, as we are using a theoretical additive combination, wrong results appear as false synergistic or antag-
onistic results. However, the increase in the precision of the obtained CI with CISNE is not limited to reduce false 
positives, as shown in previous sections. If we consider a synergistic combination, the standard method can lead 
to wrong results of additive (or, even worse, antagonistic!) effects, and CISNE allows to minimize the probability 
of obtaining these wrong results as well.
Conclusions
Combinations Therapies that present a synergistic effect is a valuable resource for the treatment of the most 
dreadful diseases. We have demonstrated in this article however that the accuracy whereby the available schemes 
determine whether a drug combination is synergistic or not can easily lead to false positives and false negatives. 
We have also identified the main source of inaccuracy and fixed it. Our new implementation allows us to deter-
mine dose-effect relationships more accurately, that conveys a more precise determination of the CI. In particular, 
our Monte Carlo simulations show that the number of false positives that can be obtained from the mathematical 
analysis can be reduced by a factor of 10. We find that the defects of the standard method become specially dam-
aging whenever the experimental data deliver values of the fraction of the population affected fa larger than 0.9 
or smaller than 0.1. Although our new method presents advantages for any range of experimental data, we stress 
that the use of our new method becomes especially relevant in these cases.
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